Compositions and methods for the treatment of presbyopia
The invention provides compositions and methods for the treatment of presbyopia. In a preferred embodiment correction of presbyopia occurs without reduction in distance vision acuity. The compositions of the invention preferably contain a muscarinic agonist and a cycloplegic agent.
1. An opthalmological composition for the treatment of presbyopia comprising from about 0.5% to about 2.5% w/v of a muscarinic agonist and a cycloplegic agent, wherein w/v denotes weight by volume.
2. The composition of claim 1 wherein the muscarinic agonist is selected from the group consisting of pilocarpine, aceclidine, carbachol, talsaclidine, sabcomeline, cevimeline, WAY-132983, AFB267B (NGX267), AC-42, AC-260584, 77-LH-28-1, and LY593039 or a pharmaceutically acceptable salt, ester, or prodrug thereof.
3. The composition of claim 1 wherein the cycloplegic agent is selected from the group consisting of pirenzepine, tropicamide, cyclopentolate hydrochloride, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), AF-DX 384, methoctramine, tripitramine, darifenacin, solifenacin, tolterodine, oxybutynin, ipratropium, oxitropium, tiotropium, otenzepad and a combination thereof.
4. The composition of claim 1 wherein the ratio of muscarinic agonist to cycloplegic agent is greater than about 25:1.
5. The composition of claim 4 wherein the ratio of muscarinic agonist to cycloplegic agent is greater than about 40:1.
6. A method of treating presbyopia comprising administering a therapeutically effective amount of a composition of claim 1 to a patient in need thereof.
7. The method of claim 6 wherein distance vision acuity of the patient is not reduced.
8. An opthalmological composition for the treatment of presbyopia comprising from about 0.5% to about 2.5% w/v pilocarpine or a pharmaceutically acceptable salt, ester, or prodrug thereof and a cycloplegic agent, wherein w/v denotes weight by volume.
9. The composition of claim 8 wherein the cycloplegic agent is selected from the group consisting of pirenzepine, tropicamide, cyclopentolate hydrochloride, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), AF-DX 384, methoctramine, tripitramine, darifenacin, solifenacin, tolterodine, oxybutynin, ipratropium, oxitropium, tiotropium, otenzepad and a combination thereof.
10. The composition of claim 8 wherein the cycloplegic agent is at a concentration from about 0.010% to about 0.1% w/v.
11. The composition of claim 10 wherein pilocarpine is at a concentration of about 1.5% w/v.
12. A method of treating presbyopia comprising administering a therapeutically effective amount of a composition of claim 8 to a patient in need thereof.
13. The method of claim 12 wherein distance vision acuity of the patient is not reduced.
14. An opthalmological composition for the treatment of presbyopia comprising from about 0.5% to about 2.5% w/v pilocarpine or a pharmaceutically acceptable salt, ester, or prodrug thereof and tropicamide, wherein w/v denotes weight by volume.
15. The composition of claim 14 wherein tropicamide is at a concentration from about 0.010% to about 0.1% w/v.
16. The composition of claim 15 wherein pilocarpine is at a concentration of about 1.5% w/v and tropicamide is at a concentration of about 0.035% w/v.
17. The composition of claim 15 wherein pilocarpine is at a concentration of about 0.95% w/v and tropicamide is at a concentration of about 0.015% w/v.
18. A method of treating presbyopia comprising administering a therapeutically effective amount of a composition of claim 14 to a patient in need thereof.
19. The method of claim 18 wherein distance vision acuity of the patient is not reduced.